Remegen 荣昌生物
8 significant filings since 29 May 2026: 6 on buyback, 1 on earnings pre-announcement and 1 on new listing. The latest, on 3 Sep 2026: 荣昌生物关于2026年第一次以集中竞价交易方式回购公司股份的进展公告. On 6 Aug 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 1,145.45% from the same period a year earlier.
自 29 May 2026 起有 8 份重大公告：buyback 6 份、earnings pre-announcement 1 份、new listing 1 份。最新一份（3 Sep 2026）：荣昌生物关于2026年第一次以集中竞价交易方式回购公司股份的进展公告。6 Aug 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 1,145.45%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 For this company, 1 of 8 rated reports was Neutral or lower. 本公司 8 份评级研报中 1 份为中性或以下。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 4 Sep 2026 | 3 | — |
| 西南证券 | 杜向阳,汤泰萌 | Unrated | 1 Apr 2026 | 1 | — |
| 国金证券 | 甘坛焕 | Buy 买入 | 31 Mar 2026 | 2 | — |
| 华安证券 | 谭国超,任婉莹 | Buy 买入 | 13 Jan 2026 | 2 | — |
| 浦银国际证券 | 阳景,胡泽宇 | Neutral 中性 | 4 Nov 2025 | 1 | 96.70 |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 9 reports. 每行为该券商近十二个月的最新研报；9 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。